Drug Trial Radar · NCT07706673
ESCUDDO Long Term Follow Up
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
13,700
Planned (sponsor's estimate)
Start
Aug 11, 2026
Primary completion
Oct 1, 2030
Study completion Jan 15, 2031
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- Collaborators
- Merck Sharp and Dohme LLC
- First posted
- Jul 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This phase IV trial evaluates the long term protection provided by either one or two doses of the 9v human papillomavirus (HPV) vaccine for participants who were part of the ESCUDDO study.
Conditions
- Human Papillomavirus Infection
- Human Papillomavirus-Related Malignant Neoplasm
Interventions
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine AdsorbedBiological
Given IM in ESCUDDO (NCT03180034)
Recombinant Human Papillomavirus Nonavalent VaccineBiological
Given intramuscularly (IM) in ESCUDDO (NCT03180034)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparison of incident persistent human papillomavirus (HPV) infection related to vaccine types observed during long-term follow-up study (LFTU) and the combined ESCUDDO base and LTFU studies; in recipients of single dose and 2 doses of the 9vHPV vaccineTime frame: 7 to 10 years after first HPV vaccination
- Comparison of cumulative persistent HPV infection (Base Study + LTFU)Time frame: 1 to 10 years after first HPV vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Agencia Costarricense de Investigaciones Biomédicas (ACIB)
Liberia, Guanacaste Province, Costa Rica
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.